Cargando…

Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis

BACKGROUND: Hospitals expanded critical care capacity during the COVID-19 pandemic by treating COVID-19 patients with high-flow nasal cannula oxygen therapy (HFNC) in non-traditional settings, including general internal medicine (GIM) wards. The impact of this practice on intensive care unit (ICU) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverstein, William K., Zipursky, Jonathan S., Amaral, Andre C., Leis, Jerome A., Strong, Laura, Nardi, Julie, Weinerman, Adina S., Wong, Brian M., Stroud, Lynfa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854405/
https://www.ncbi.nlm.nih.gov/pubmed/36662403
http://dx.doi.org/10.1007/s11606-022-07949-9
_version_ 1784873111106093056
author Silverstein, William K.
Zipursky, Jonathan S.
Amaral, Andre C.
Leis, Jerome A.
Strong, Laura
Nardi, Julie
Weinerman, Adina S.
Wong, Brian M.
Stroud, Lynfa
author_facet Silverstein, William K.
Zipursky, Jonathan S.
Amaral, Andre C.
Leis, Jerome A.
Strong, Laura
Nardi, Julie
Weinerman, Adina S.
Wong, Brian M.
Stroud, Lynfa
author_sort Silverstein, William K.
collection PubMed
description BACKGROUND: Hospitals expanded critical care capacity during the COVID-19 pandemic by treating COVID-19 patients with high-flow nasal cannula oxygen therapy (HFNC) in non-traditional settings, including general internal medicine (GIM) wards. The impact of this practice on intensive care unit (ICU) capacity is unknown. OBJECTIVE: To describe how our hospital operationalized the use of HFNC on GIM wards, assess its impact on ICU capacity, and examine the characteristics and outcomes of treated patients. DESIGN: Retrospective cohort study of all patients treated with HFNC on GIM wards at a Canadian tertiary care hospital. PARTICIPANTS: All patients admitted with COVID-19 and treated with HFNC on GIM wards from December 28, 2020, to June 13, 2021, were included. MAIN MEASURES: We combined administrative data on critical care occupancy daily with chart-abstracted data for included patients to establish the total number of patients receiving ICU-level care at our hospital per day. We also collected data on demographics, medical comorbidities, illness severity, COVID-19 treatments, HFNC care processes, and patient outcomes. KEY RESULTS: We treated 124 patients with HFNC on the GIM wards (median age 66 years; 48% female). Patients were treated with HFNC for a median of 5 days (IQR 3 to 8); collectively, they received HFNC for a total of 740 hospital days, 71% of which were on GIM wards. At peak ICU capacity strain (144%), delivering HFNC on GIM wards added 20% to overall ICU capacity by managing up to 14 patients per day. Patients required a median maximal fraction of inspired oxygen of 80% (IQR 60 to 95). There were 18 deaths (15%) and 85 patients (69%) required critical care admission; of those, 40 (47%) required mechanical ventilation. CONCLUSIONS: With appropriate training and resources, treatment of COVID-19 patients with HFNC on GIM wards appears to be a feasible strategy to increase critical care capacity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-022-07949-9.
format Online
Article
Text
id pubmed-9854405
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-98544052023-01-23 Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis Silverstein, William K. Zipursky, Jonathan S. Amaral, Andre C. Leis, Jerome A. Strong, Laura Nardi, Julie Weinerman, Adina S. Wong, Brian M. Stroud, Lynfa J Gen Intern Med Original Research BACKGROUND: Hospitals expanded critical care capacity during the COVID-19 pandemic by treating COVID-19 patients with high-flow nasal cannula oxygen therapy (HFNC) in non-traditional settings, including general internal medicine (GIM) wards. The impact of this practice on intensive care unit (ICU) capacity is unknown. OBJECTIVE: To describe how our hospital operationalized the use of HFNC on GIM wards, assess its impact on ICU capacity, and examine the characteristics and outcomes of treated patients. DESIGN: Retrospective cohort study of all patients treated with HFNC on GIM wards at a Canadian tertiary care hospital. PARTICIPANTS: All patients admitted with COVID-19 and treated with HFNC on GIM wards from December 28, 2020, to June 13, 2021, were included. MAIN MEASURES: We combined administrative data on critical care occupancy daily with chart-abstracted data for included patients to establish the total number of patients receiving ICU-level care at our hospital per day. We also collected data on demographics, medical comorbidities, illness severity, COVID-19 treatments, HFNC care processes, and patient outcomes. KEY RESULTS: We treated 124 patients with HFNC on the GIM wards (median age 66 years; 48% female). Patients were treated with HFNC for a median of 5 days (IQR 3 to 8); collectively, they received HFNC for a total of 740 hospital days, 71% of which were on GIM wards. At peak ICU capacity strain (144%), delivering HFNC on GIM wards added 20% to overall ICU capacity by managing up to 14 patients per day. Patients required a median maximal fraction of inspired oxygen of 80% (IQR 60 to 95). There were 18 deaths (15%) and 85 patients (69%) required critical care admission; of those, 40 (47%) required mechanical ventilation. CONCLUSIONS: With appropriate training and resources, treatment of COVID-19 patients with HFNC on GIM wards appears to be a feasible strategy to increase critical care capacity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-022-07949-9. Springer International Publishing 2023-01-20 2023-04 /pmc/articles/PMC9854405/ /pubmed/36662403 http://dx.doi.org/10.1007/s11606-022-07949-9 Text en © The Author(s), under exclusive licence to Society of General Internal Medicine 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
spellingShingle Original Research
Silverstein, William K.
Zipursky, Jonathan S.
Amaral, Andre C.
Leis, Jerome A.
Strong, Laura
Nardi, Julie
Weinerman, Adina S.
Wong, Brian M.
Stroud, Lynfa
Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
title Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
title_full Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
title_fullStr Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
title_full_unstemmed Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
title_short Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
title_sort effect of ward-based high-flow nasal cannula (hfnc) oxygen therapy on critical care utilization during the covid-19 pandemic: a retrospective cohort analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854405/
https://www.ncbi.nlm.nih.gov/pubmed/36662403
http://dx.doi.org/10.1007/s11606-022-07949-9
work_keys_str_mv AT silversteinwilliamk effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis
AT zipurskyjonathans effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis
AT amaralandrec effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis
AT leisjeromea effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis
AT stronglaura effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis
AT nardijulie effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis
AT weinermanadinas effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis
AT wongbrianm effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis
AT stroudlynfa effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis